For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $1.58 in the prior trading day, Pliant Therapeutics Inc (NASDAQ: PLRX) closed at $1.62, up 2.53%. In other words, the price has increased by $2.53 from its previous closing price. On the day, 1.64 million shares were traded.
Ratios:
Our goal is to gain a better understanding of PLRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.91 and its Current Ratio is at 10.91. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 17 ’25 when Coulie Bernard sold 52,419 shares for $11.20 per share. The transaction valued at 587,150 led to the insider holds 430,517 shares of the business.
Cummings Keith Lamont sold 20,148 shares of PLRX for $225,680 on Jan 17 ’25. The Chief Financial Officer now owns 262,608 shares after completing the transaction at $11.20 per share. On Jan 17 ’25, another insider, Hull Hans, who serves as the Chief Business Officer of the company, sold 15,936 shares for $11.20 each. As a result, the insider received 178,501 and left with 211,558 shares of the company.
Stock Price History:
Over the past 52 weeks, PLRX has reached a high of $16.52, while it has fallen to a 52-week low of $1.26. The 50-Day Moving Average of the stock is -80.71%, while the 200-Day Moving Average is calculated to be -86.21%.
Shares Statistics:
A total of 60.86M shares are outstanding, with a floating share count of 52.99M. Insiders hold about 13.46% of the company’s shares, while institutions hold 96.73% stake in the company.
Earnings Estimates
The company has 9.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.46 and low estimates of -$0.9.
Analysts are recommending an EPS of between -$1.77 and -$2.84 for the fiscal current year, implying an average EPS of -$2.33. EPS for the following year is -$2.68, with 11.0 analysts recommending between -$1.07 and -$6.64.
